BiliaryTractCancer near Teaneck, NJ

Biography: Jedd Wolchok, MD, PhD, FASCO, is the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. Dr. Wolchok was most recently Chief of the Immuno-Oncology Service and held The Lloyd J. Old Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center and remains Professor of Medicine at Weill Cornell Medical College. Dr. Wolchok is a clinician-scientist exploring innovative immunotherapeutic strategies in laboratory models, and a principal investigator in numerous pivotal clinical trials. Dr. Wolchok helped establish immunotherapy as a standard approach to cancer treatment and was instrumental in the clinical development leading to the approval of ipilimumab and the combination of nivolumab and ipilimumab for advanced melanoma. He supervises an NIH R01-funded basic science laboratory which is focused on investigating novel immunotherapeutic agents in pre-clinical laboratory models. The focus of his translational research laboratory is to investigate innovative means to modulate the immune response to cancer as well as to better understand the mechanistic basis for sensitivity and resistance to currently available immunotherapies. Dr. Wolchok received his BA degree from Princeton University, and his MS, PhD and MD degrees from New York University. Dr. Wolchok has received numerous honors for his work including: American Association for Cancer Research (AACR) Richard and Hinda Rosenthal Memorial Award, the Giants of Cancer Care in Melanoma Award, the Berson Alumni Achievement Award in Clinical and Translational Science and the Zelmanovich Young Alumni Achievement Award from NYU Grossman School of Medicine, the Alfred Taubman Prize for Excellence in Translational Medical Research (Univ of Michigan) and has been designated a Fellow of the American Society of Clinical Oncology (FASCO). Most recently, he has been awarded the the Distinguished Alumni Award at MSK, the AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research, the ESMO Award for Immuno-Oncology and the David Karnofsky Award from ASCO. Dr. Wolchok has served on the Board of Directors of ASCO and the Society for Immunotherapy of Cancer (SITC) and currently is the Treasurer of SITC. He is an elected member of the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP) and is Chair of the Melanoma Committee for the ECOG-ACRIN NCI cooperative group. He is a full member of the Ludwig Institute for Cancer Research and center director for the Parker Institute of Cancer Immunotherapy.

Care Philosophy: I am a medical oncologist who specializes in cancers of the lung and thymus. I work closely with our multidisciplinary team of expert thoracic surgeons, radiation oncologists, interventional radiologists, palliative care/pain management specialists, and nutritionists to provide comprehensive care for our patients. I view each patient and their disease as unique and work to manage their treatment accordingly, always keeping their goals in mind. In order to provide new hopes for the future of lung cancer treatment, our division is also involved in clinical research focusing on precsion medicine, immunotherapy, and novel therapeutics as well as laboratory research to better understand this disease.

Biography: Dr. Amy Tiersten, MD is a Hematology Specialist who practices in New York, NY. She is 61 years old and has been practicing for 35 years. Dr. Amy Tiersten, MD is affiliated with Mount Sinai Hospital.

Biography: Myron M. Studner Professor of Cancer Research and Professor of Medicine and Epidemiology at Columbia University, Associate Director for Population Science, Leader of the Prevention, Control, and Disparities Program for the Herbert Irving Comprehensive Cancer Center at Columbia, and Co-Director of the Cancer Prevention Center of New York Presbyterian Hospital Dr. Neugut is a medical oncologist with a particular interest in gastroIntestinal tract cancers, especially of colorectal and gasteric cancers. Under the auspices of Columbia's MD/PhD program, he received his MD and a PhD in Pathobiology in 1977. He did his training in Internal Medicine at the Albert Einstein College of Medicine and fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center. He returned to Columbia University as an Andrew Mellon Fellow in Epidemiology and Medicine to obtain an MPH in Epidemiology in 1983. Dr. Neugut then joined the faculty at Columbia University with appointments in Medicine and Epidemiology. As both a practicing medical oncologist and cancer epidemiologist, Dr. Alfred Neugut's major interests have been on GI tract cancers, notably the epidemiology of colorectal adenomas and cancer, as well as colonoscopic screening. He serves as co-principal investigator of the Long Island Breast Cancer Study Project, a large multi-center effort to explore environmental causes of breast cancer on Long Island. Most recently, his efforts have focused on more clinical topics, such as the epidemiology of second malignancies and the use of chemotherapy and radiation therapy among elderly cancer patients. Dr. Neugut focuses a great deal on racial disparities in incidence and survival from cancer and, in particular, variations across subgroups of people of African descent. He leads two large training grants in cancer-related population sciences that together fund 15 pre and postdoctoral trainees in cancer epidemiology, biostatistics, and environmental health sciences, and serves as a mentor to a number of junior faculty.

Biography: Dr. Catherine Shu isthe Price Family Associate Professor of Medicine anda board-certified medical oncologist specializing in the treatment of thoracic cancers, with a focus on lung cancer. She received her undergraduate degree from Princeton University, followed by her M.D. from Columbia University College of Physicians and Surgeons. After residency at Columbia University Medical Center, Dr. Shu completed her fellowship at Memorial Sloan Kettering Cancer Center, where she was appointed Chief Fellow. She currently serves as the Director of the Thoracic Medical Oncology Service. She has presented her work at numerous international conferences and has published in the top peer-reviewed oncology journals. She treats the entire spectrum of lung cancer, but has a particular interest in earlier stage and surgically resectable disease, specifically on drug combinations to help improve survival in this setting. Additionally, she devotes part of her research effort to patients with targetable mutations, helping to determine the best sequence of treatments. Of all her achievements, she is proudest to be able to offer individualized and compassionate care to each and every one of her patients. She understands that each patient and family carries forth a different set of beliefs, goals, and needs. Working alongside an exceptional multidisciplinary team, she is dedicated to improving the survival and bettering the quality of life of her patients.